Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Interest Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Interest Expenses for 3 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest Expenses changed N/A to $3.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.0 million, a 58.5% decrease, with the full-year FY2024 number at $13.5 million, down 57.63% from a year prior.
  • Interest Expenses was $3.2 million for Q3 2025 at Inhibrx Biosciences, up from $3.1 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $8.2 million in Q4 2023 to a low of $2.7 million in Q1 2025.
  • A 3-year average of $5.6 million and a median of $5.4 million in 2024 define the central range for Interest Expenses.
  • Biggest YoY gain for Interest Expenses was 41.41% in 2025; the steepest drop was 66.92% in 2025.
  • Inhibrx Biosciences' Interest Expenses stood at $8.2 million in 2023, then plummeted by 34.8% to $5.4 million in 2024, then crashed by 40.66% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Interest Expenses are $3.2 million (Q3 2025), $3.1 million (Q2 2025), and $2.7 million (Q1 2025).